Table 6. Postoperative adjuvant immunotherapy for NSCLC.
| Trial | Eligible patients | Intervention following surgery | Estimated enrolment (N) | Primary endpoint | Median follow-up | HR |
|---|---|---|---|---|---|---|
| IMpower 010 | IB–IIIA NSCLC |
Arm A: platinum doublet (4 cycles) followed by atezo (16 cycles). Arm B: platinum doublet (4 cycles) followed by best supportive care |
1,280 | DFS | 32.8 m | 0.66 (95% CI: 0.50–0.88) in PD-L1 + II–IIIA patients |
| PEARLS/KEYNOTE-091 | IB–IIIA NSCLC |
Arm A: (optional chemotherapy) pembro (1 year). Arm B: (optional chemotherapy) placebo (1 year) |
1,080 | DFS | 35.6 m | 0.76 (95% CI: 0.63–0.91) in ITT patients. 0.82 (95% CI: 0.57–1.18) in PD-L1 TPS ≥50% patients |
| ANVIL | IB–IIIA NSCLC |
Arm A: (optional chemotherapy and RT) nivolumab (1 year). Arm B: (optional chemotherapy and RT) observation |
903 | DFS/OS | NG | NG |
| BR31 | IB–IIIA NSCLC |
Arm A: (optional chemotherapy and RT if N2) duva (1 year). Arm B: (optional chemotherapy and RT if N2) placebo (1 year) |
1,360 | DFS | NG | NG |
| ALCHEMIST | IB–IIIA NSCLC |
Arm A: platinum doublet (4 cycles). Arm B: platinum doublet (4 cycles) followed by pembrolizumab (17 cycles). Arm C: platinum doublet plus pembrolizumab (4 cycles) followed by pembrolizumab (additional 13 cycles) |
1,263 | DFS/OS | NG | NG |
NSCLC, non-small cell lung cancer; atezo, atezolizumab; pembro, pembrolizumab; duva, durvalumab; DFS, disease-free survival; OS, overall survival; NG, not given; ITT, intention-to-treat; TPS, tumor proportion score; PD-L1, programmed cell death-ligand 1.